By Joel Rubenstein, GINN Focal Point Nicotine Replacement Therapy (NRT) was born not out of global health ambition—but naval necessity. In the 1960s, Swedish submariners needed a smoke-free and spit-free way to consume nicotine underwater. The solution was nicotine gum—commissioned by the Swedish Navy and developed by local pharmaceutical companies. What started as a practical…
Sweden is poised to become the first country in the world to reach “smoke-free” status—defined as a smoking rate below 5%. According to newly released data, this achievement is not the product of prohibitionist measures but of pragmatic, evidence-based harm reduction policies, with nicotine pouches playing a central role—especially among women. The report Power in…
Several European Union Member States have formally called on the European Commission to introduce stricter regulation of vaping products and emerging nicotine alternatives. This coordinated initiative reflects growing concern among national governments about rising youth experimentation and the evolving nicotine product landscape. It also signals that the revision of the Tobacco Products Directive (TPD) and…
A newly published systematic review and network meta-analysis by La Rosa et al. (2025) offers valuable insights into the oral health effects of non-combustible nicotine products (NCNPs). As these products gain popularity as reduced-risk alternatives to smoking, understanding their broader health impact—including on oral health—is critical for clinicians, policymakers, and harm reduction advocates alike. The…
On January 7, 2025, the American Heart Association (AHA) released a comprehensive policy statement examining the cardiovascular health implications of smokeless oral nicotine products. Published in Circulation, the statement evaluates emerging products such as tobacco-free nicotine pouches, lozenges, gums, tablets, and gummies, many of which contain synthetic nicotine. This is the AHA’s first detailed update…
I’m proud to announce that Joel Rubenstein has joined GINN as our newest Focal Point. Joel brings more than 25 years of leadership in the health, wellness, and consumer healthcare sectors, with a proven track record across CPG, Rx, and OTC categories. His career spans US and Global marketing roles at Pfizer, Novartis and GlaxoSmithKline;…
Sweden is on track to become the first country in Europe to achieve smoke-free status, defined as having fewer than 5% of the adult population smoking. Behind this milestone is a powerful shift in consumer behavior—particularly among women—driven by the rising popularity of oral nicotine pouches. A recent press release from Smoke-Free Sweden highlights how…
Balancing Harm Reduction and Public Health in the Global Nicotine Dialogue As policymakers prepare for the WHO’s 11th Conference of the Parties (COP11) to the Framework Convention on Tobacco Control (FCTC), the question of whether to ban flavours in nicotine pouches and other reduced-risk products is front and center. While the WHO frames flavours as…
A new preprint study conducted by researchers at Emplicure provides promising evidence that bioceramic calcium sulfate-based nicotine pouches may offer faster and more efficient nicotine delivery than conventional cellulose-based formats. The findings, currently hosted on Research Square, could shape future innovations in nicotine pouch design and regulation. The study, titled Comparative study of calcium sulfate…
At the 2025 Global Forum on Nicotine in Warsaw, Emplicure Chief Clinical, Regulatory & Quality Officer Dr. Anna Franzén delivered a compelling presentation during the panel “Nicotine Pouches: What’s the Real Story?”. What Dr. Franzén Shared Dr. Franzén emphasised three critical pillars for nicotine pouches: Established safety of medicinal nicotine — highlighting how regulatory frameworks for nicotine…